Advertisement
News
Advertisement

Miraculins Announces Board Members

Mon, 04/16/2012 - 11:45am
The Associated Press

(http://www.miraculins.com/)

Miraculins Inc. (TSX VENTURE:MOM), a medical diagnostic company

focused on acquiring, developing and commercializing diagnostic tests

and risk assessment technologies for unmet clinical needs is pleased

to announce that at the Company's Annual and Special Meeting of

shareholders held today (the "Meeting"), the following individuals

were elected to the board of directors; Michael Stasiuk, Noah Billick,

Harry Bloomfield, William (Bill) Roberts and Christopher Moreau. All

five individuals were current members of the board of directors of

Miraculins Inc. and had let their names stand for re-election at the

Meeting.

Following the Meeting, the board of directors of the Company held a

board meeting at which time Harry Bloomfield was appointed interim

Chairman of the board, succeeding David Howard who did not stand for

re-election at the Meeting.

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on

acquiring, developing and commercializing non-invasive tests for unmet

clinical needs. The Company's PreVu test is a revolutionary new

coronary artery disease risk assessment technology that measures

cholesterol levels in a patient's skin non-invasively, painlessly and

without the need for fasting. The PreVu Non-Invasive Skin Cholesterol

Point of Care (POC) Test technology has been cleared for sale by

Health Canada and CE-Marked in the European Union. PreVu has

previously been successfully test marketed in North America on a

limited basis. Miraculins additional programs include a research use

only ELISA kit for the detection of PSP94; and a suite of biomarkers

to aid in the early detection of the devastating disease of pregnancy

known as preeclampsia. The Company's preeclampsia program is being

advanced in partnership with Alere, Inc. (NYSE:ALR) (formerly known as

Inverness Medical Innovations), one of the world's largest diagnostic

companies.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute

forward-looking information within the meaning of applicable Canadian

provincial securities legislation (collectively, "forward-looking

statements"). These forward-looking statements relate to, among other

things, our objectives, goals, targets, strategies, intentions, plans,

beliefs, estimates and outlook, including, without limitation, our

anticipated future operating results, and can, in some cases, be

identified by the use of words such as "believe," "anticipate,"

"expect," "intend," "plan," "will," "may" and other similar

expressions. In addition, any statements that refer to expectations,

projections or other characterizations of future events or

circumstances are forward-looking statements.

These statements reflect management's current beliefs and are based on

information currently available to management. Certain material

factors or assumptions are applied in making forward-looking

statements, and actual results may differ materially from those

expressed or implied in such statements. Important factors that could

cause actual results to differ materially from these expectations

include, among other things: Miraculins' early stage of development,

lack of product revenues and history of operating losses,

uncertainties related to clinical trials and product development,

rapid technological change, uncertainties related to forecasts,

competition, potential product liability, additional financing

requirements and access to capital, unproven markets, supply of raw

materials, income tax matters, management of growth, partnerships for

development and commercialization of technology, effects of insurers'

willingness to pay for products, system failures, dependence on key

personnel, foreign currency risk, risks related to regulatory matters

and risks related to intellectual property and other risks detailed

from time to time in Miraculins' filings with Canadian securities

regulatory authorities, as well as Miraculins' ability to anticipate

and manage the risks associated with the foregoing. Additional

information about these factors and about the material factors or

assumptions underlying such forward-looking statements may be found in

the body of this news release. Miraculins cautions that the foregoing

list of important factors that may affect future results is not

exhaustive. When relying on Miraculins' forward-looking statements to

make decisions with respect to Miraculins investors and others should

carefully consider the foregoing factors and other uncertainties and

potential events.

These risks and uncertainties should be considered carefully and

prospective investors should not place undue reliance on the

forward-looking statements. Although the forward-looking statements

contained in this press release are based upon what management

believes to be reasonable assumptions, Miraculins cannot provide

assurance that actual results will be consistent with these

forward-looking statements. Miraculins undertakes no obligation to

update or revise any forward-looking statement.

PreVu@ is a registered trademark of Miraculins Inc. All Rights

Reserved. 2012.

Neither TSX Venture Exchange nor its Regulation Services Provider (as

that term is defined in the policies of the TSX Venture Exchange)

accepts responsibility for the adequacy or accuracy of this release.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading